AMINOCAPROIC Drug Patent Profile
✉ Email this page to a colleague
When do Aminocaproic patents expire, and what generic alternatives are available?
Aminocaproic is a drug marketed by Hikma, Abraxis Pharm, Baxter Hlthcare, Hospira, Luitpold, Amneal, Annora Pharma, Aurobindo Pharma, Belcher, Carnegie, Epic Pharma Llc, Florida, Sunny, Taro, Tulex Pharms Inc, Vistapharm Llc, Ani Pharms, Edenbridge Pharms, MSN, and Optimus. and is included in twenty-four NDAs.
The generic ingredient in AMINOCAPROIC is aminocaproic acid. There are six drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the aminocaproic acid profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Aminocaproic
A generic version of AMINOCAPROIC was approved as aminocaproic acid by LUITPOLD on December 1st, 1987.
Summary for AMINOCAPROIC
US Patents: | 0 |
Applicants: | 20 |
NDAs: | 24 |
Raw Ingredient (Bulk) Api Vendors: | 183 |
Clinical Trials: | 37 |
Patent Applications: | 4,286 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for AMINOCAPROIC |
DailyMed Link: | AMINOCAPROIC at DailyMed |
Recent Clinical Trials for AMINOCAPROIC
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Minia University | Phase 3 |
NYU Langone Health | N/A |
Assiut University | Phase 4 |